Experimental Pediatric Ulcerative Colitis Drug Picks Up Orphan Drug Status

Experimental Pediatric Ulcerative Colitis Drug Picks Up Orphan Drug Status
shutterstock_168768398AvaxiaBiologics,Inc. recently announced that the US Food and Drug Administration (FDA) granted their lead experimental drug AVX-470 Orphan Drug Designation for the treatment of pediatric ulcerative colitis. The news comes after the company previously announced the results of their Phase 1b clinical trial for AVX-470. Ulcerative colitis (one of the two most common types of Inflammatory Bowel Disease) is characterized by inflammation of the large intestine. The symptoms for UC include abdominal cramping, diarrhea, and bloody stools, with approximately 25% of the cases occurring in young people who are less than 20 years old. The disease impacts normal childhood development due to deficient dietary intake accompanied with impaired absorption and enteric blood loss occurring at a key stage of childhood development. AVX-470 is the first specific gut-targeted anti-TNF antibody being developed as a therapeutic for ulcerative colitis clinical applications that can be administered orally, thus offering a significant a
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *